Surgical treatment, whole brain irradiation (WBI) and stereotactic radiation therapy (RT) are the main treatment strategies for solitary brain metastases. Applying additional boost to the bed of removed metastatic foci seems promising for enhancing local control, but increased radiation exposure affects the central regulation and processes that maintain homeostasis. The purpose of the study was to evaluate optimization of adjuvant RT with xenon due to its neurotrophic and neuroprotective effects.
16 patients of the control group received WBI with additional boost once a day (60 Gy in 15 fractions), while 12 patients of the main group received similar RT plus inhalations of a xenon/oxygen mixture twice a week. Clinical and neurological examination was performed and the quality of life was assessed (using QLQ-C15 and BN-20 + 2 questionnaires) for all patients during the treatment. Adaptation reactions were identified and the ratio of their anti-stress/stress types (R as/s) was calculated for integral evaluation of the body condition, individual testing tension (Ut) at the Yin Tang point was studied and EEG parameters were analyzed.
Only patients receiving xenon reported reduced rates of headaches and dizziness, disorders of higher nervous activity, reduced degrees of movement disorders; RT course for these patients was performed in compliance with the accompanying therapy. Assessment of the quality of life by the end of the treatment showed significant improvement in such criteria as physical health and loss of appetite, as well as pain relief, in contrast to the control group. Negative dynamics of integral body parameters, R as/s and Ut was lower than in the control group, and some EEG parameters were normalized after xenon therapy.
Xenon therapy is an effective optimization method for radiation treatment of patients with brain metastases. Its radioprotective and stress-limiting effects allow reduction of adverse effects and toxicity and improvement of the quality of life of patients.
Clinical trial identification
Legal entity responsible for the study
Rostov Scientific Research Institute of Oncology, Russia
All authors have declared no conflicts of interest.